Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avricore Health Inc V.AVCR

Alternate Symbol(s):  AVCRF

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.


TSXV:AVCR - Post by User

Bullboard Posts
Post by kingposton Apr 01, 2016 1:20pm
198 Views
Post# 24720638

Teva chooses JV structure to enter Japan with Generics..

Teva chooses JV structure to enter Japan with Generics..

Teva Pharmaceutical Industries (TEVA +0.5%) and Takeda Pharmaceutical Company Limited (OTCPK:TKPHF)(OTCPK:TKPYYestablish a venture in Japan with the aim of marketing off-patent (generic) drugs. The Nagoya-based company, called Teva Takeda Yakuhin Ltd., will be led by industry veteran Hiroshi Matsumori.

Takeda expects the venture to be both earnings and cash flow accretive this year and thereafter. Teva expects accretion to non-GAAP EPS this year as well.

Japan is faced with a silver tsunami which is a aging population making it a great market for generics...Many other asian countries are also facing the same situation and reducing drug costs will push generic sales for years... Joint ventures, with good partners,  are a a good structure choice for opening new markets...

Bullboard Posts